RhumbLine Advisers
RDHL

RhumbLine Advisers’s Redhill Biopharma RDHL Stock Holding History

RhumbLine Advisers’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
13,755
+8,639
+169% +$7.97K ﹤0.01% 3882
2026
Q1 		$3.81K Buy
5,116
+2,438
+91% +$2.57K ﹤0.01% 3897
2025
Q4 		$2.75K Buy
2,678
+910
+51% +$1.22K ﹤0.01% 3965
2025
Q3 		$3.83K Hold
1,768
– – ﹤0.01% 3933
2025
Q2 		$3.37K Buy
1,768
+380
+27% +$774 ﹤0.01% 3949
2025
Q1 		$3.69K Buy
1,388
+190
+16% +$885 ﹤0.01% 3940
2024
Q4 		$7.35K Buy
1,198
+219
+22% +$1.67K ﹤0.01% 3918
2024
Q3 		$8.54K Buy
979
+222
+29% +$2.19K ﹤0.01% 3911
2024
Q2 		$7.02K Sell
757
-450
-37% -$5K ﹤0.01% 4028
2024
Q1 		$15.9K Sell
1,207
-187
-13% -$3.33K ﹤0.01% 3796
2023
Q4 		$50.9K Buy
1,394
+1,273
+1,052% +$26K ﹤0.01% 3631
2023
Q3 		$1.54K Hold
121
– – ﹤0.01% 4140
2023
Q2 		$3.65K Buy
+121
New +$6.97K ﹤0.01% 4134

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $3.08B AUM 27.39% 1-Year Est. Return

RhumbLine Advisers's RDHL Position: Q2 2026 in Review

RhumbLine Advisers increased its Redhill Biopharma (RDHL) stake by 169% in Q2 2026, buying an estimated $7.97K and bringing the position to 13,755 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3882.

RhumbLine Advisers first reported a position in RDHL in Q2 2023 and has held it in 13 quarters since. The position peaked at $50.9K in Q4 2023. 14 funds tracked by Wall St. Rank hold RDHL as of Q2 2026.

  • RhumbLine Advisers held 13,755 shares of Redhill Biopharma worth $11.6K as of Q2 2026.
  • RhumbLine Advisers bought 8,639 Redhill Biopharma shares in Q2 2026, an estimated $7.97K.
  • Redhill Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3882 holding.
  • RhumbLine Advisers first reported a position in Redhill Biopharma in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Redhill Biopharma position peaked at $50.9K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.